Shots:
- Advent and GIC to acquire Sobi for ~$8B (SEK 69.4B) at $27.33/share (SEK 235) representing a premium of 34.5% to the closing price of $20.41. The offer acceptance period is expected to start on Sept 2021 and expire on Oct 21, 2021
- Sobi focuses on delivering innovative therapies and services in the areas of hematology, immunology, and specialty care & had a portfolio of 6 products & offices in ~ 30 countries, offering therapies for patients in ~ 70 countries
- Agnafit Bidco will obtain ownership of 90% of the total number of Shobi’s shares & the receipt of all necessary regulatory, governmental, or similar clearances, approvals & decisions, including from competition authorities
Click here to read full press release/ article | Ref: Sobi | Image: Sobi
The post Advent and GIC to Acquire Sobi for ~$8B first appeared on PharmaShots.
